RNAC Stock Analysis: Buy, Sell, or Hold?
RNAC - Cartesian Therapeutics, Inc. Common Stock
$10.18
0.23 (2.31%)
▲
5d:
+18.37%
30d:
+52.4%
90d:
+54.24%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When RNAC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: RNAC is 14.9% above its trading range ($8.86). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: RNAC is 14.9% above its trading range ($8.86). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: RNAC is currently trading at $10.18, which is considered extended relative to its 30-day fair value range of $6.17 to $8.86.
Technical Outlook: Technically, RNAC is showing sideways momentum. The price is approaching resistance at $9.33. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: RNAC has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.57 (+239.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, RNAC is showing sideways momentum. The price is approaching resistance at $9.33. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: RNAC has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.57 (+239.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$6.17 -
$8.86
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BEARISH: Price significantly overextended (+14.9% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 239.6% below Wall St target ($34.57)
Trading Range Analysis
30-Day Trading Range
$6.17 -
$8.86
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$5.77
Resistance Level
$9.33
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.80
Wall Street Target
$34.57
(+239.6%)
Revenue Growth (YoY)
-92.9%
Earnings Growth (YoY)
-7.4%
Share & Embed Analysis
Last updated: June 23, 2026 11:35 PM ET
Data refreshes hourly during market hours. Next update: 12:35 AM
Data refreshes hourly during market hours. Next update: 12:35 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RNAC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Blaine Davis
SELL
10591 shares
2026-01-06
Milos Miljkovic
SELL
3573 shares
2026-01-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 64 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 65 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 60 BUY |
